Armenia vs Peru: Average cost of drugs for extensively drug-resistant tuberculosis
Armenia
4,190 constant 2022 US$
in 2024
Peru
3,884 constant 2022 US$
in 2024
Armenia rank
16th
Peru rank
18th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Armenia
- Peru
How they compare
Armenia currently reports 4,190 constant 2022 US$ against 3,884 constant 2022 US$ in Peru, a difference of 306 constant 2022 US$.
That makes Armenia's figure about 1.1 times Peru's.
The two have swapped places 1 time across 6 shared years of data; in 2019 it was Peru ahead.
Armenia ranks 16th and Peru ranks 18th of 56 countries.
Peru has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Armenia | Peru | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 4,900 constant 2022 US$ | 6,264 constant 2022 US$ | 1,364 constant 2022 US$ | Peru |
| 2020s | 5,178 constant 2022 US$ | 6,019 constant 2022 US$ | 841.2 constant 2022 US$ | Peru |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Armenia or Peru?
- Armenia, at 4,190 constant 2022 US$ against 3,884 constant 2022 US$ in Peru as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Armenia and Peru?
- 306 constant 2022 US$, with Armenia ahead.
- How many years of comparable data are there for Armenia and Peru?
- 6 years are reported by both, from 2019 to 2024.
- How do Armenia and Peru rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Armenia ranks 16th and Peru ranks 18th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.